BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35347810)

  • 1. Detection of disease-causing mutations in prostate cancer by NGS sequencing.
    Mangolini A; Rocca C; Bassi C; Ippolito C; Negrini M; Dell'Atti L; Lanza G; Gafà R; Bianchi N; Pinton P; Aguiari G
    Cell Biol Int; 2022 Jul; 46(7):1047-1061. PubMed ID: 35347810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic and Germline Variants Affect Prognosis and Susceptibility in Prostate Cancer.
    Rocca C; Rocca G; Zampieri P; Dell'atti L; Bianchi N; Ippolito C; Aguiari G
    Anticancer Res; 2023 Jul; 43(7):2941-2949. PubMed ID: 37351993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis.
    Al-Toubat M; Serrano S; Elshafei A; Koul K; Feibus AH; Balaji KC
    Urol Oncol; 2023 Nov; 41(11):455.e7-455.e15. PubMed ID: 37838503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and genomic features of SPOP-mutant prostate cancer.
    Nakazawa M; Fang M; H Marshall C; Lotan TL; Isaacsson Velho P; Antonarakis ES
    Prostate; 2022 Feb; 82(2):260-268. PubMed ID: 34783071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
    Hernández-Llodrà S; Segalés L; Safont A; Juanpere N; Lorenzo M; Fumadó L; Rodríguez-Vida A; Cecchini L; Bellmunt J; Lloreta-Trull J
    Prostate; 2019 Jul; 79(10):1156-1165. PubMed ID: 31090082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinico-pathological significance of the molecular alterations of the SPOP gene in prostate cancer.
    García-Flores M; Casanova-Salas I; Rubio-Briones J; Calatrava A; Domínguez-Escrig J; Rubio L; Ramírez-Backhaus M; Fernández-Serra A; García-Casado Z; López-Guerrero JA
    Eur J Cancer; 2014 Nov; 50(17):2994-3002. PubMed ID: 25204806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct Genomic Alterations in Prostate Tumors Derived from African American Men.
    Liu W; Zheng SL; Na R; Wei L; Sun J; Gallagher J; Wei J; Resurreccion WK; Ernst S; Sfanos KS; Isaacs WB; Xu J
    Mol Cancer Res; 2020 Dec; 18(12):1815-1824. PubMed ID: 33115829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolving landscape of prostate cancer somatic mutations.
    Cotter K; Rubin MA
    Prostate; 2022 Aug; 82 Suppl 1(Suppl 1):S13-S24. PubMed ID: 35657155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
    Beltran H; Yelensky R; Frampton GM; Park K; Downing SR; MacDonald TY; Jarosz M; Lipson D; Tagawa ST; Nanus DM; Stephens PJ; Mosquera JM; Cronin MT; Rubin MA
    Eur Urol; 2013 May; 63(5):920-6. PubMed ID: 22981675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline variant screening with targeted next generation sequencing in prostate cancer: phenotype-genotype correlation.
    Çakır AY; Hekimler Öztürk K; Özorak A
    Turk J Med Sci; 2022 Feb; 52(1):131-143. PubMed ID: 34579513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of speckle-type POZ protein somatic mutations in African American prostate cancer.
    Buckles E; Qian C; Tadros A; Majumdar S; Cvitanovic J; Zabaleta J; Estrada J; Wilson J; Liu W
    Asian J Androl; 2014; 16(6):829-32. PubMed ID: 24994784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a novel germline SPOP mutation in a family with hereditary prostate cancer.
    Zuhlke KA; Johnson AM; Tomlins SA; Palanisamy N; Carpten JD; Lange EM; Isaacs WB; Cooney KA
    Prostate; 2014 Jun; 74(9):983-90. PubMed ID: 24796539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic alterations related to HPV infection status in a cohort of Chinese prostate cancer patients.
    Lang B; Cao C; Zhao X; Wang Y; Cao Y; Zhou X; Zhao T; Wang Y; Liu T; Liang W; Hu Z; Tian X; Zhang J; Yan Y
    Eur J Med Res; 2023 Jul; 28(1):239. PubMed ID: 37461056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.
    Boysen G; Rodrigues DN; Rescigno P; Seed G; Dolling D; Riisnaes R; Crespo M; Zafeiriou Z; Sumanasuriya S; Bianchini D; Hunt J; Moloney D; Perez-Lopez R; Tunariu N; Miranda S; Figueiredo I; Ferreira A; Christova R; Gil V; Aziz S; Bertan C; de Oliveira FM; Atkin M; Clarke M; Goodall J; Sharp A; MacDonald T; Rubin MA; Yuan W; Barbieri CE; Carreira S; Mateo J; de Bono JS
    Clin Cancer Res; 2018 Nov; 24(22):5585-5593. PubMed ID: 30068710
    [No Abstract]   [Full Text] [Related]  

  • 15. Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors.
    Decker B; Karyadi DM; Davis BW; Karlins E; Tillmans LS; Stanford JL; Thibodeau SN; Ostrander EA
    Am J Hum Genet; 2016 May; 98(5):818-829. PubMed ID: 27087322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 alterations of hormone-naïve prostate cancer in the Chinese population.
    Liu Z; Guo H; Zhu Y; Xia Y; Cui J; Shi K; Fan Y; Shi B; Chen S
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):482-491. PubMed ID: 33214693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline genetic variants in men with prostate cancer and one or more additional cancers.
    Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
    Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53, SPOP and PIK3CA Genes Status in Prostate Cancer.
    Al Zoubi MS; Otoum R; Alorjani MS; Al Bashir S; Al Trad B; Abualrja MI; Al-Khatib SM; Al-Batayneh K
    Asian Pac J Cancer Prev; 2020 Nov; 21(11):3365-3371. PubMed ID: 33247697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
    Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A
    Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using next-generation sequencing (NGS) platform to diagnose pathogenic germline BRCA1/2 mutations from archival tumor specimens.
    Ong PY; Poon SL; Tan KT; Putti TC; Ow SGW; Chen SJ; Chen CH; Lee SC
    Gynecol Oncol; 2019 Nov; 155(2):275-279. PubMed ID: 31481248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.